EvolveImmune Therapeutics is a company developing precision cancer medicines to deliver patient outcomes compared to current anti-cancer therapies.

EvolveImmune Therapeutics

AC Immune SA is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It integrates diagnostic and therapeutic candidates in its pipeline.

AC Immune SA

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

Wei Wu

Dan Segal

Amit Etkin

Alto Neuroscience, Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Metric
Company Name	EvolveImmune Therapeutics	AC Immune SA	Alto Neuroscience, Inc.	Pfizer Inc.
Symbol			ANRO	PFE
MSH ID	COM:EVOLVEIMMUNE	COM:ACIMMUNE	COM:ALTONEUROSCIENCE	COM:PFIZER
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Drug Manufacturers - General
Country	US	CH	US	US
Stage			Series C
Employee Count			67	88K
Website	evolveimmune.com	acimmune.com	altoneuroscience.com	pfizer.com
LinkedIn			altoneuroscience	pfizer
Founders

Metric
Market Cap	338.20M	160.65B
Enterprise Value
Monthly Web Traffic	4.46K	1.84M
Web Traffic Growth	-0.41	0.15
Valuation
Raised Capital	45M	1B

Metric
Revenue				58.50B
Revenue (LTM)
Revenue (NTM)
Gross Profit				29.28B
EBITDA				10.53B
Operating Income				4.24B
Net Income				2.12B
EPS				0.38
Diluted EPS				0.38
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.52
Operating Profit Margin				0.06
EBITDA Margin				0.18
Net Profit Margin				0.04
Return on Equity				0.02
Return on Assets				0.01
Return on Capital Employed				5.56

COM:EVOLVEIMMUNE

EvolveImmune Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				14.35
P/B Ratio				1.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				3.21
EV Multiple				17.74

Metric
Days Sales Outstanding				79.90
Days Payables Outstanding				72.06
Days Inventory Outstanding				155.46
Operating Cycle				230.19
Cash Conversion Cycle				160.85
Asset Turnover				141.27

Metric
Operating Cash Flow				8.70B
Free Cash Flow				4.79B
Cash Flow to Debt				0.12
Operating Cash Flow/Sales				0.16
Free Cash Flow Yield				0.05

Metric
Cash & Equivalents				2.85B
Accounts Receivable				347M
Inventory				10.19B
Goodwill				67.78B
Debt to Capitalization				0.45
Debt to Assets				0.30
Current Ratio				2.38
Quick Ratio				94.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.01
R&D to Revenue				0.17
SG&A to Revenue